Better understanding of blood vessel constrictor needed to harness its power for patients

September 18, 2008
Better understanding of blood vessel constrictor needed to harness its power for patients
Dr. Adviye Ergul, physiologist in the MCG Schools of Medicine and Graduate Studies. Credit: Medical College of Georgia

To harness endothelin-1's power to constrict blood vessels and help patients manage high blood pressure or heart failure, scientists must learn more about how endothelin functions naturally and in disease states, says a Medical College of Georgia researcher.

Despite strong laboratory evidence that blocking endothelin-1 receptors would be an effective, targeted therapy for these two major health problems, the drugs failed patients, says Dr. Adviye Ergul, physiologist in the MCG Schools of Medicine and Graduate Studies.

"These endothelin-1 receptors are logical targets for drugs to treat hypertension because of their key role in vasoconstriction, but the targets are moving and we don't know how one target plays off another," says Dr. Ergul, who discussed novel aspects of endothelin receptor interaction during the 62nd High Blood Pressure Research Conference and Workshop in Atlanta.

"The current thinking in pharmacology is one hormone, one receptor equals boom: the effect. I think cells are much smarter," she says. This week, Dr. Ergul challenged colleagues across the country to consider emerging evidence that usual receptor communication is likely more complex than they thought and that disease may significantly alter communication.

Endothelin-1 receptors are known to interact: one way blood vessels keep a healthy tone, for example, is that a and b receptors on smooth muscle cells prompt constriction while b receptors on the lining of blood vessels work with nitric oxide to promote relaxation. Endothelin-1 receptors on the kidneys are a player as well, helping wring out excess water and salt. "There is a delicate balance," says Dr. Ergul.

But there's apparently more to the relationships. She holds up a handful of recent journal articles which reflect mounting evidence that receptors actively work as teams of two or more. That teamwork could change their function. New technology enables scientists to literally watch receptors move closer together on a cell surface, clearly indicating that something is going on.

"Numerous drugs have been developed that are antagonists that can block these receptors with the idea they can be used in hypertension and heart failure. In animal models, they worked well," she says. But in clinical trials they failed badly; a drug for heart failure actually worsened problems such as labored breathing and swelling in patients already having difficulty moving blood through their body.

The first antagonists blocked both known receptors: a and b; the next generation blocked one or the other but still didn't work. A notable exception is endothelin-1 antagonists that reduce excessive pressure and tissue buildup inside the blood vessels of patients with pulmonary hypertension. In addition to constricting blood vessels, endothelin-1 can help blood vessels grow bigger but too much can result in protein deposits that stiffen blood vessel walls.

Scientists have been scratching their heads over why blocking these receptors hasn't panned out; they've even looked for an "atypical" receptor that might explain it. But Dr. Ergul, an expert on endothelin-1's role in diabetes, believes the unexpected results are better explained by poorly understood relationships in normal and disease states. "How receptors dimerize, how they get closer together on the cell surface, likely needs to affect our drug design," she says.

Source: Medical College of Georgia

Explore further: UB spinoff company For-Robin moves one step closer to human clinical trials

Related Stories

UB spinoff company For-Robin moves one step closer to human clinical trials

October 17, 2017
Scientists from For-Robin Inc., a University at Buffalo biotechnology spinoff, have published new scientific results showing that the company's cancer-fighting antibody can target, penetrate and kill human tumor cells effectively.

Likely new treatment target identified for diabetic retinopathy

October 10, 2017
In oxygen-compromising conditions like diabetes, the body grows new blood vessels to help, but the result is often leaky, dysfunctional vessels that make bad matters worse.

Healing molecule discovery could reduce limb amputations for diabetes patients

October 4, 2017
Scientists have discovered new insights into a molecule which is part of the body's tissue repair system, in a finding which could help treat non-healing wounds and injuries, such as diabetic foot.

How the lungs of premature babies can undergo damage

September 29, 2017
Premature babies that need ventilation to support their breathing often suffer from a condition known as bronchopulmonary dysplasia. Researchers at the Helmholtz Zentrum München, partner in the German Center for Lung Research ...

Researchers report new paths to glaucoma treatment

September 19, 2017
Researchers at the Center for Vascular Research, within the Institute for Basic Science (IBS), have identified a new mechanism involved in the development and progression of glaucoma, and found a potential therapeutic option ...

Therapeutic fusion protein could mitigate blood vessel damage from cardiovascular disease

August 15, 2017
Scientists from Boston Children's Hospital Vascular Biology Program have revealed an engineered fusion protein that could recover blood vessel health following the onset of hypertension, atherosclerosis, stroke, heart attack, ...

Recommended for you

Inflammation trains the skin to heal faster

October 18, 2017
Scars may fade, but the skin remembers. New research from The Rockefeller University reveals that wounds or other harmful, inflammation-provoking experiences impart long-lasting memories to stem cells residing in the skin, ...

Large variety of microbial communities found to live along female reproductive tract

October 18, 2017
(Medical Xpress)—A large team of researchers from China (and one each from Norway and Denmark) has found that the female reproductive tract is host to a far richer microbial community than has been thought. In their paper ...

Study of what makes cells resistant to radiation could improve cancer treatments

October 18, 2017
A Johns Hopkins University biologist is part of a research team that has demonstrated a way to size up a cell's resistance to radiation, a step that could eventually help improve cancer treatments.

New approach helps rodents with spinal cord injury breathe on their own

October 17, 2017
One of the most severe consequences of spinal cord injury in the neck is losing the ability to control the diaphragm and breathe on one's own. Now, investigators show for the first time in laboratory models that two different ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

New method to measure how drugs interact

October 17, 2017
Cancer, HIV and tuberculosis are among the many serious diseases that are frequently treated with combinations of three or more drugs, over months or even years. Developing the most effective therapies for such diseases requires ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.